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Background
Hereditary angioedema (HAE) is a disease transmitted
by autosomal dominant inheritance, characterized by
quantitative and / or functional deficiency of C1 inhibi-
tor (C1-INH), which causes episodes of swelling, with
involvement of many organs. HAE is currently divided
into three groups. The HAE type III is a less frequent
disorder that mainly affects women and is characterized
by normal levels and activity of C1-INH.
Methods
Literature review and case description.
Results
We assessed a 33 years old female with episodes of lip
angioedema and facial edema since March 2014, with no
pruritus, with paresthesia, sometimes associated with suffo-
cation, lasting up to 5 days despite of the use of corticoster-
oids and antihistamines. Patient remained with attacks twice
a week with edema in different regions of the body. She did
not use inhibitors of angiotensin converting enzyme, but she
used contraceptive containing estrogen. The causes of aller-
gic or acquired angioedema were ruled out. Laboratory
investigation showed normal results for inhibitor quantita-
tive and functional C1 and normal levels of C4 and C1q.
The change of the oral contraceptive to another free of
estrogen did not bring remission of episodes of edema. In
June 2014 the patient was seen in the emergency room with
dysphonia and suffocation. The patient was submitted to the
standard treatment for anaphylaxis and a subcutaneous dose
of Icatibant 30 mg. She had significant improvement of the
symptoms in less than 1 hour. After that episode we decided
to treat her with Danazol 200mg daily. Since then this
patient had no more symptoms.
Conclusions
We report a case of hereditary angioedema type III who
received Icatibant as a therapeutic trial because of an
acute laryngeal edema. In HAE type III laboratory investi-
gation is normal and clinical evidence becomes critical to
the diagnosis. In this case, the immediate response to the
use of the bradykinin receptor inhibitor reinforced the
clinical evidence and led to the early diagnosis of heredi-
tary angioedema type III.
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